Both parties’ patents in dispute relate to chemical compounds that are appropriate for use in pharmaceutical drugs, in particular for the treatment of flaviviridae infections such as hepatitis C virus infections. Ruling that Idenix’ patent lacks a sufficiently clear description, and that Gilead’s patent is novel and inventive, the Oslo District Court declared Idenix’ patent invalid and handed down the judgment in favour of Gilead.
A full summary of this case has been published on Kluwer IP Law.
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
